How old is your brain? Ask every hospital

8162
https://www.isi.edu/news/53927/how-old-is-your-brain-ask-all-the-hospitals/
Story Headline and Deck – USC News *
How Old Is Your Brain? Ask All The Hospitals
Body Copy *
You’re worried you are at risk for a neurological disease, so you get an MRI scan of your brain.

Option #1: Your doctor could predict your risk based on all the MRIs she’s seen in her career.

Option #2: Using artificial intelligence, a machine learning (ML) model trained over all the MRI scans stored in the medical records of a single hospital could predict your risk.

Option #3: Using the ML technique of Federated Learning, a group of hospitals could collaborate and jointly train an ML model for risk prediction using all the MRI scans from all the hospitals within the group, while protecting patient privacy.

In general, the more medical data an ML model is trained on, the better the predictions will be, leading to improved patient care and better outcomes. (In other words, choose option three!)

A team at USC Viterbi’s Information Sciences Institute (ISI), led by Professor Jose-Luis Ambite and his USC Department of Computer Science Ph.D. candidate Dimitris Stripelis, has proposed a novel architecture to address some of the most critical challenges observed in Federated Learning environments. They will present this architecture as part of the 2023 International Workshop on Health Intelligence (W3PHIAI 2023) held in Washington, D.C. on Feb. 13-14, 2023, in association with the 37th AAAI Conference on Artificial Intelligence.

The Challenges in Federated Learning
Federated Learning (FL) is a method used to train a machine learning model collaboratively, using data from various distributed sources (“data silos”), without sharing the data. FL is often used when the privacy of the data must be maintained.

In the example above, the data silos are the individual hospitals. The private data are the MRI scans.

The ISI team proposes a general-purpose federated learning platform architecture, called Federated Learning INTegration (FLINT), that addresses three specific challenges of federated learning that frequently arise in the biomedical space.

Challenge #1: The Learning Task
A successful FL system must first be able to perform the “learning task.” This means that, with the information that is garnered from the various silos, the collaborative model can, to some accuracy, make predictions.

The ISI research team used MetisFL, the FL platform they have developed with significant funding from DARPA and NIH. They have used MetisFL in neuroimaging tasks, such as Brain Age Gap Estimation (BrainAGE) and Alzheimer’s Disease prediction.

The BrainAGE learning task is to predict the age of a human brain from a structural MRI scan. The difference between the predicted and chronological age value is a biomarker of brain pathologies.

Stripelis, co-author of the paper explained, “You have MRI scans distributed across hospitals and you want to analyze what is the difference between the true chronological and the predictive chronological age of the subject. Because the larger the difference between those two values is, the greater the risk of developing a neurological disease. It’s an indicator – or biomarker – of a neurological disease.”

This was the learning task: can the model accurately predict the BrainAGE given an MRI, if it has been trained within the proposed FLINT architecture?

Stripelis said, “We show that yes, using our system, you can actually learn that task.” Ambite added, “And the architecture is secure. No private data leaves a hospital and the models are trained under homomorphic encryption.” (Homomorphic encryption allows computations to be performed on data without decrypting it.)

Challenge #2: Schema Harmonization
Stripelis continued, “The second challenge has to do with the data integration component, and specifically schema and data harmonization.” Silos often have different data formats, values, schemata and access patterns. In other words, different silos have different characteristics and specifications. So the researchers need to make sure that the data used for learning can be made compatible.

Stripelis gave an example: “Let’s say you have one column that is called ‘DOB’ in one table and ‘birth_date’ in another table. They represent exactly the same attribute, under a different name. Or one site measures weight in kilograms and another in pounds. You have to harmonize the attributes and values in order to do meaningful analysis; that’s data integration.”

The field of data integration has developed many methods to address this challenge, which are used by the ISI team in the FLINT architecture.

Challenge #3: Missing Values
The third component is missing values. “One interesting aspect that arises in federated data silos is that, with all these different datasets, some might have missing values, even completely missing attributes,” said Stripelis.

Missing values are a critical problem in federated learning and in machine learning in general. Stripelis explained, “Often, if a single value is missing from a record, we need to either drop the record altogether or impute (fill in) the missing value.”

The ISI team proposes an architecture to address this.

The Proposed Architecture
“We propose to solve this problem through principled data integration and imputation techniques, so that learning can be done over data that ‘makes sense.’ This is an exciting and ambitious vision that we wanted to share with the research community, but the work is still in progress, so we are presenting it first in a workshop,” said Stripelis.

The team will present the FLINT architecture at the upcoming 2023 International Workshop on Health Intelligence (W3PHIAI 2023). This year marks the seventh annual W3PHIAI, focused on “Saving Lives with AI.”

The workshop program is an extension of the 37th AAAI Conference on Artificial Intelligence. Run by the largest professional organization in the field, the Association for the Advancement of Artificial Intelligence (AAAI), this conference aims to promote research in artificial intelligence and scientific exchange among AI researchers, practitioners, scientists, and engineers in affiliated disciplines.

The post How old is your brain? Ask every hospital appeared first on USC News.

Medicare Advantage enrollment outpaces — and nearly overcomes — traditional Medicare

8148

Medicare Advantage Enrollment Outpaces –and Nearly Overcomes– Traditional Medicare, New USC Study Finds

Story Headline and Deck – USC News *
Medicare Advantage Enrollment Outpaces –and Nearly Overcomes– Traditional Medicare, New USC Study Finds

Medicare Advantage plans have seen a more than 300% increase in enrollment–with payment policy yet to catch up.
Body Copy *
Despite a dramatic increase in the size of the Medicare-eligible population due to an aging society, enrollment in traditional Medicare declined by almost 3% since 2006. This was the result of a significant increase in the share of beneficiaries enrolling in Medicare Advantage plans, according to a new USC Schaeffer study published this week in the February 2023 issue of Health Affairs.

Medicare Advantage (MA) allows enrollees to get their health and prescription coverage through plans administered by private insurance companies as an alternative to traditional Medicare.

“Private plan predecessors of MA were originally set up as a sort of experiment and, for a number of years, participation in these programs grew very slowly,” says Paul Ginsburg, senior fellow at the USC Schaeffer Center and a co-author of the study. “In the last decade, the program has grown considerably, which has real implications for how we pay for it.” Ginsburg is a professor of practice at the USC Price School of Public Policy.

Urban and rural areas see increased Medicare Advantage participation
The research team analyzed Medicare enrollment data from 2006 to 2022. Over this time, MA enrollment increased by 337% (22.2 million beneficiaries). This change was so rapid, that while the total number of Medicare beneficiaries grew from 41.8 million in 2006 to 63 million in 2022, enrollment in traditional Medicare actually declined by 1 million (-2.9%).

All told, in 2022 MA penetration reached 49.9% nationally, and 24% of Medicare beneficiaries with Parts A and B lived in a county with adjusted MA penetration equal to or exceeding 60%.

The authors point out that this trend is not confined to urban areas: 31% of rural counties had MA penetration of 45% or greater in 2022.

“Medicare beneficiaries are reforming the program with their feet,” says Erin Trish, co-director of the Schaeffer Center and associate professor at the USC Mann School of Pharmacy and Pharmaceutical Sciences. “Across the country, they are consistently choosing MA plans over traditional Medicare.”

While beneficiaries are reforming Medicare through their choice of plan, MA payment policy hasn’t kept up
This has important policy implications. MA payment policy was designed in an era when the bulk of enrollees were in traditional Medicare. The way plans are paid is a complicated formula, but the base of it is set by the average cost per beneficiary in traditional Medicare in each county. However, what becomes of that policy when a diminishing minority of Medicare enrollees are in traditional Medicare?

“We know that MA plans are getting overpaid relative to the costs of providing care to comparable beneficiaries in traditional Medicare, and this has contributed to the magnitude of extra benefits offered to MA enrollees,” says Ginsburg. “While this is appealing to consumers, this is increasing federal spending and accelerating the rate at which the Medicare trust fund is being exhausted.”

For policymakers grappling with the issues of Medicare’s financial solvency and providing coverage for an aging population, this paper highlights important trends that suggest MA’s market share will continue to increase. Policy discussions about paying for the program need to recognize this. The researchers previously developed a proposal to move MA payment policy away from costs in traditional Medicare to competitive-bidding benchmarks, which is one potential policy solution.

“We can’t continue to think of Medicare Advantage as an appendage of the traditional Medicare program,” Ginsburg says. “We are at a point where the tail is wagging the dog.”

The study’s co-authors also included the USC Schaeffer Center’s Samuel Valdez, Samantha Randall and Steven M. Lieberman. This work was supported by a grant from Arnold Ventures.

The post Medicare Advantage enrollment outpaces — and nearly overcomes — traditional Medicare appeared first on USC News.

With fanfare and festivity, USC Mann School marks a new era

With an explosion of streamers and a crowd of more than 300 well-wishers, USC’s newly named pharmacy school on Wednesday marked a game-changing moment in its 118-year history.

Unveiling the new name on the building’s facade, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences formally celebrated the generous $50 million gift from the Alfred E. Mann Foundation for Biomedical Engineering to name and further strengthen the school.

The gift ensures the USC Mann School’s rise as a leading research and educational institution, one of the top-ranked pharmacy schools in the nation. The naming gift also underscores the school’s prominence in education, research and community care in Los Angeles.

Our pharmacy school … has innovation built into its own DNA.

Carol L. Folt, USC president

“Our pharmacy school, in that spirit, has innovation built into its own DNA,” said USC President Carol L. Folt, noting the late Alfred E. Mann’s own extensive list of patented inventions to improve health — among them, the rechargeable pacemaker.

Like its namesake, USC Mann also has a track record of invention, with faculty researchers who have achieved 35 patents. It also has a history of launching innovative degree programs, including the first doctorate degree in regulatory science.

“In the coming century, biomedical engineering will drive some of the most consequential breakthroughs,” Folt said. “The school is now partnering with USC Dornsife to turn plastic waste from the Great Pacific Garbage Patch into medicines and other much-needed products.”

USC Mann School: Large footprint, and growing

The school has a large footprint in the region that will only grow now with help from the Mann gift.

“We train more than half of all pharmacists in Southern California right here,” Folt said, gesturing toward the facade of USC Mann at the Health Sciences Campus.

The donation — the largest naming donation for a school of pharmacy in California — starts a new chapter for the school, funding student scholarships and faculty recruitment while helping build a research infrastructure across USC’s University Park and Health Sciences campuses.

The name alone sets it apart from dozens of the more than 140 peer institutions across the country as it honors the late, prolific biodevice developer Alfred E. Mann, who was also a member of the USC Board of Trustees.

Mann’s gift for the school is part of a major initiative launched by the university and the Alfred E. Mann Foundation for Biomedical Engineering that will significantly expand USC and Southern California’s health sciences, biotech and engineering footprint. Since Mann first generously donated the gift in 1998, it has grown to more than $230 million.

Last November, Folt announced that the gift, in addition to providing a naming gift to the pharmacy school, would also enable the naming of the Alfred E. Mann Department of Biomedical Engineering within the USC Viterbi School of Engineering to boost its educational and research endeavors.

Suzanne Nora Johnson, who is the chair of the USC Board of Trustees and who knew Mann, said his spirit of ingenuity was legendary. The legacy his foundation now leaves to USC Mann and his namesake Department of Biomedical Engineering is especially fitting.

Al cared less about stockpiling wealth — and more about serving humanity.

Suzanne Nora Johnson, USC trustee chair

“Big Al,” as Johnson and others liked to call the inventor, was a remarkable entrepreneur, founding 17 companies over seven decades yet remaining dedicated to solving medical issues. His products included a prosthetic for the blind, Second Sight; a rechargeable and implantable pacemaker, Pacesetter; and drug therapies for diabetes, cancer and other diseases under his company MannKind Corp.

“Al cared less about stockpiling wealth — and more about serving humanity,” Johnson said. “It’s not hyperbole to say: The companies he founded helped the blind to see, the deaf to hear and the physically challenged to walk.”

Legacy lives on through USC Mann School graduates

And now his legacy will live on through thousands of future USC Mann graduates.

In its 118-year history, the school has a history of pushing pharmacy education beyond its traditional scope, positioning its faculty and graduates as first-line medical staff and health care providers. For example, USC Mann led Los Angeles’ rollout of the COVID-19 vaccine during the pandemic, overseeing the nation’s largest distribution site, at Dodger Stadium.

Even before the pandemic, USC Mann was providing important services for the improvement of community health. It offers drug takeback days each year to properly dispose of leftover medicines and provides consultations to Angelenos to help them manage their medications.

“Very few pharmacy schools have received naming gifts, and still fewer have been bestowed with a significant endowment,” said Vassilios Papadopoulos, dean of USC Mann. “What this means for our community — and how it will redirect what we can achieve — is beyond measure.”

The Mann Foundation gift will fuel a strategic plan for the school that focuses in part on curricular changes that will “ensure the school’s long-standing place at the vanguard of progress in pharmacy and pharmacological sciences,” Papadopoulos said.

“We will continue to transform how students are educated, in all of our degree programs, so they remain prepared to continue pushing forward the frontiers of pharmacy and health care to benefit individuals and communities everywhere,” he added.

Later this year, the school will open a new community pharmacy — its fifth — in South Los Angeles, reaffirming its commitment to alleviating health disparities created by “pharmacy deserts.” This pharmacy will offer chronic disease management as well as health and wellness education.

USC Mann also stands out among peer institutions because its new name was broadened to encompass opportunities for its graduates in the entire spectrum of pharmaceutical discovery and health application, from basic discovery to experimental therapeutics and all the way to clinical trials and implementation and analysis of impact. Students can emerge as innovative entrepreneurs conducting drug research in the pharmaceutical and biomedical fields to develop and test new drug therapies. Some may even launch their own startups, joining a growing and influential biotech sector that now spans the Southern California coastline from L.A. to San Diego.

USC Mann School trains leaders in research, industry and regulation

With more than 20 degree programs, the school also primes its graduates for leadership roles in research, industry and federal regulation. One of Wednesday’s speakers was Renita Moradian, the first student to receive the USC Mann School’s new bachelor’s of science degree in pharmacology and drug development.

The Mann name will continue to flourish through the discoveries generated in the school’s labs and from the future pharmacy leaders we train.

Vassilios Papadopoulos, USC Mann dean

“In 2018, when I first received my bachelor’s degree, I remember feeling very lucky. USC had given me countless opportunities that exceeded every expectation I had as a first-generation immigrant and as a first-generation college student,” said Moradian, who is completing her PharmD. “What I didn’t know at the time is the extent to which I would continue to change and grow while pursuing my doctorate degree here.”

In the early days of USC Mann, the majority of students trained to be community pharmacists, and that is still the case at many pharmacy schools. But today — and for many years now — the school has trained pharmacists, pharmaceutical scientists, medicinal chemists, pharmacologists, drug developers, clinical trialists, economists specializing in drug policy and costs, and regulatory scientists for all potential jobs, not for a specific one, Papadopoulos said.

“As health care needs change, we will have the agility, coupled with the know-how and determination, to pursue innovations that anticipate and are ahead of the curve in meeting those changes,” said Papadopoulos. “The Mann name will continue to flourish through the discoveries generated in the school’s labs and from the future pharmacy leaders we train.”

The post With fanfare and festivity, USC Mann School marks a new era appeared first on USC News.

USC awarded grant to help diverse populations access cancer clinical trials

8146 school/unit website *

Stand Up To Cancer has awarded USC Norris a $550,000 Grant to Help Diverse Populations Access Cancer Clinical Trials

Story Headline and Deck – USC News *
Stand Up To Cancer has awarded USC Norris a $550,000 Grant to Help Diverse Populations Access Cancer Clinical Trials
Body Copy *

To reduce health disparities and advance health equity, it is crucial that people from diverse backgrounds participate in clinical trials, so researchers can better understand the risks as well as the benefits novel treatments present to different populations.

Now, a two-year grant from Stand Up To Cancer(R) (SU2C) will fund a new program at the USC Norris Comprehensive Cancer Center to eliminate barriers and facilitate access to early phase cancer clinical trials in traditionally underserved communities in Los Angeles County. This grant was funded as part of the SU2C Diversity in Early Development Clinical Trials Research Grants Program and is supported by a sponsorship from Janssen Pharmaceutical Companies of Johnson & Johnson. As a part of SU2C’s Health Equity Initiative, the program aims to create unique and replicable approaches that engage medically underserved communities in Phase 1 and Phase 2 cancer clinical trials.

“We are very excited to work with SU2C to improve access to early therapeutic trials among diverse patients through an innovative collaboration with hospitals that serve underrepresented patients within the Los Angeles County Department of Health Services, the Lazarex Foundation, and the Men’s Cancer Network,” said Chanita Hughes Halbert, PhD, associate director for cancer equity at USC Norris cancer center. “By working collaboratively with these stakeholders, we will be able to develop, implement, and evaluate multilevel approaches to improve referrals to early phase trials and enhance enrollment outcomes.”

Led by Dr. Hughes Halbert and co-led by Anthony El-Khoueiry, MD, associate director for clinical research at the cancer center, the research team implement a project entitled Eliminating Enrollment Barriers to Early Phase Trials in a Diverse Population in Los Angeles County. The team will first identify barriers to referral of underserved patients from the center’s diverse catchment area for early phase therapeutic trials. They will then implement and evaluate a multilevel, multi-component program for removing those barriers and improving early phase therapeutic trials referral and enrollment among underserved patients and explore the impact of remote clinical trials on enhancing the enrollment of these patients.

“Cancer clinical trial diversity in Los Angeles needs to be improved significantly to represent and serve our underserved communities,” said Dr. El-Khoueiry, who is also an associate professor of clinical medicine at the Keck School of Medicine of USC. “Through a more strategic, collaborative approach with oncology care providers, facilitated referral and recruitment processes involving private and public health systems collaboration, a more targeted review of our patient demographics and further exploration of remote clinical trials, we hope to advance cancer health equity by facilitating access to early phase trials among our community’s medically underserved patients.”

Additionally, as part of the project, USC Norris cancer center researchers will participate in the SU2C Community Engagement Innovation Summit, connecting with other leaders in health equity to identify common goals and approaches to overcome existing barriers through community outreach.

“The SU2C Diversity in Early Development Clinical Trials Research Grant Program offers a unique opportunity to leverage USC Norris faculty members’ extensive experience increasing access to clinical trials among individuals historically underrepresented in trials,” said Caryn Lerman PhD, director of the USC Norris Comprehensive Cancer Center, H. Leslie and Elaine S. Hoffman Chair in Cancer Research, and associate dean for cancer programs in the Keck School of Medicine of USC. “Leveraging the center’s robust early phase clinical trials program, this team aims to develop scalable models to advance equity in clinical trials.”

Additional researchers on the team include Jacob Thomas, MD, Jorge Nieva, MD, Lourdes Baezconde-Garbanati, PhD, Myles Cockburn, PhD and Jennifer Tsui, PhD, all members of the USC Norris Comprehensive Cancer Center and faculty from the Keck School of Medicine of USC.

SU2C raises funds to accelerate the pace of groundbreaking research that provides new therapies to patients quickly and saves lives now. By galvanizing the entertainment industry, SU2C has set out to generate awareness, educate the public on cancer prevention, and help more people diagnosed with cancer become long-term survivors.

About USC Norris Comprehensive Cancer Center

At the USC Norris Comprehensive Cancer Center, more than 250 dedicated physicians and scientists are leading the fight to make cancer a disease of the past. As one of the eight original National Cancer Institute-designated Comprehensive Cancer Centers in the United States, USC Norris has revolutionized cancer research, treatment, and prevention for nearly 50 years. Multidisciplinary teams provide the latest evidence-based care at USC Norris Cancer Hospital, a 60-bed hospital, as well as outpatient clinics throughout Los Angeles and Orange counties.

For more information, visit https://uscnorriscancer.usc.edu

The post USC awarded grant to help diverse populations access cancer clinical trials appeared first on USC News.

USC-led studies point the way to broadly effective treatments for ALS

8130

on your school/unit website *
https://stemcell.keck.usc.edu/broadly-effective-treatments-for-als/
Story Headline and Deck – USC News *
USC Stem Cell-led studies point the way to broadly effective treatments for ALS
Body Copy *
Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years. In the quest to find a cure for these patients, a team of researchers led by USC Stem Cell scientist Justin Ichida has identified two promising avenues for developing new treatments for diverse forms of this devastating disease, which is also known as amyotrophic lateral sclerosis or Lou Gehrig’s disease. Their findings are published in a pair of studies: the first appearing in the journal Cell Stem Cell on February 2, and the second in the journal Cell on February 7.

“A minority of patients have a variety of genetic causes of ALS that can be inherited within families, and a majority have what is known as “sporadic” disease because its causes are unknown,” said Gabriel Linares, a postdoc in the Ichida lab and a co-first author on both studies. “This makes it a difficult challenge to find one treatment that will work for all patients with ALS.”

To meet this challenge, the researchers collected skin or blood samples from patients with both familial and sporadic ALS. The scientists reprogrammed the skin and blood cells into motor neurons, which are the nerve cells responsible for movement that degenerate in the disease. These patient-derived motor neurons provided an opportunity to screen thousands of FDA-approved drugs and drug-like molecules to find ones that might be effective against multiple forms of ALS.

In the Cell Stem Cell study, co-first authors Linares and Yichen Li found that several of the most effective drugs and drug-like molecules increased the activity of androgens, the well-known group of sex hormones that include testosterone. However, because androgen-boosting drugs could have undesirable or unsafe side effects for patients with ALS, the scientists aimed to identify a genetic change that might yield similar results.

To accomplish this, they leveraged a public bioinformatics database known as Connectivity Map, developed by the Broad Institute of Harvard and MIT. By analyzing this vast database of information about how drugs affect the genetic landscape underpinning diseases, the scientists accurately predicted that suppressing the SYF2 gene would increase the survival of motor neurons derived from patients with diverse forms of ALS. In addition, suppressing this gene reduced neurodegeneration, motor dysfunction, and other symptoms in mice with ALS.

“What’s really exciting is that SYF2 suppression improved symptoms and pathology related to a protein called TDP-43, which can become toxic and is implicated in close to 97 percent of cases of ALS,” said Li, a postdoc in the Ichida Lab.

In the second study published in Cell, co-first authors Shu-Ting (Michelle) Hung and Linares detail how inhibiting a protein, the PIKFYVE kinase, could represent another effective strategy for treating many different forms of ALS.

In an extensive series of experiments, the researchers inhibited PIKFYVE using the drug apilimod, as well as through genetic and RNA-based approaches, in fruit flies, roundworms, mice, and motor neurons derived from patients with different forms of ALS.

They found that inhibiting PIKFYVE reduced neurodegeneration, improved motor function, and lengthened life by stimulating motor neurons to clear toxic proteins through a process of exocytosis, in which membrane-bound sacs envelop and actively transport waste to the exterior of the cell.

“We were able to pinpoint precisely how PIKFYVE inhibition mitigates neurodegeneration, which is important for informing the development of new targeted treatments,” said Hung, a PhD student in the Ichida Lab.

Ichida, who is the John Douglas French Alzheimer’s Foundation Associate Professor of Stem Cell Biology and Regenerative Medicine at USC, and a New York Stem Cell Foundation-Robertson Investigator, added: “Our discoveries bring us closer to achieving our big picture goal: finding treatments that can be broadly effective for all patients who suffer from ALS.”

Additional co-authors on both studies are: Yunsun Eoh, Manuel Santana, Jonathan Chang, and Joscany Perez from USC; and Wen-Hsuan Chang, Stacee Mendonca, Sarah Hong, and Samuel V. Alworth from AcuraStem, Inc.

For the Cell Stem Cell study, co-authors also include: Hung, Jasper Rubin-Sigler, Wenxuan Guo, Yi-Hsuan Huang, Nomongo Dorjsuren, Michael Chickering, Hao-Jen Deng, Kieu-Tram Bach, and Kamden Gray from USC; Johnny Yu and Hani Goodarzi from the University of California, San Francisco; Tze-Yuan Cheng, Chi Chou Huang, and James Lee from Leica Microsystems; and Jeffrey Rosenfeld from Loma Linda University.

For the Cell study, additional co-authors include: Li, Yingxiao Shi, Sarah Perry, Alexander Couto, Jesse Lai, Eric Hendricks, Yaoming Wang, Berislav V. Zlokovic, and Dion K. Dickman from USC; Gopinath Krishnan and Fen-Biao Gao from the University of Massachusetts; Chuol Kueth, Samantha Macklin-Isquierdo, and Daniela C. Zarnescu from Penn State University; and Sarah Duhaime, Claudia Maios, and J. Alex Parker from the Universite de Montreal.

Both studies were supported by federal funding the National Institutes for Health (grants R00NS077435, R01NS097850, 2R01NS097850, R01NS131409, R44NS097094) and U.S. Department of Defense (grants W81XWH-15-1-0187, W81XWH-20-1-0424, W81XWH-21-1- 0168, and W81XWH-21-1-0131). Whole-genome sequencing was provided by the University of Washington Center for Mendelian Genomics with additional federal funding from the NIH (grants UM1 HG006493, U24 HG008956, and S10OD021553). The studies were also supported by private funding from the Donald E. and Delia B. Baxter Foundation, Tau Consortium, Frick Foundation for ALS Research, Muscular Dystrophy Association, New York Stem Cell Foundation, Alzheimer?s Drug Discovery Foundation, Association for Frontotemporal Degeneration, Pape Adams Foundation, John Douglas French Alzheimer?s Foundation, Harrington Discovery Institute, Merkin Family Foundation, USC Broad Innovation Award, Southern California Clinical and Translational Science Institute, and a Broad Postdoctoral Fellowship.

The Cell Stem Cell study received additional support from the California Institute for Regenerative Medicine (CIRM grant DISC2-12158), the ALS Association (grants 22-PDF-588 and 984923, and the Milton Safenowitz Postdoctoral Fellowship), Keck School of Medicine of USC Regenerative Medicine Initiative, and USC Alzheimer?s Disease Research Center.

The Cell study received additional funding from the NIH (grants NS111414, R01NS091299, R37NS057553, R01NS101986, and an NIH Diversity Supplement), CIRM (grant DISC2COVID19-11901), and Target ALS Foundation.

Ichida is co-founder and Alworth is co-founder and CEO of AcuraStem, Inc., and are bound by confidentiality agreements that prevent them from disclosing details of their financial interests in this work. Chang, Mendonca, and Hong are employees of AcuraStem, Inc. Ichida is also a co-founder of Modulo Bio, serves on the scientific advisory boards of AcuraStem, Spinogenix, Synapticure, and Vesalius Therapeutics, and is a paid employee of BioMarin Pharmaceutical. In addition, Zlokovic is a co-founder of ZZ Biotech and chairman of its scientific advisory board, Parker is a co-founder of Modelis, and Gao receives research funding from Stealth BioTherapeutics.

Suggested social media post (wording that appears with your story on Facebook or Twitter). Ideally 140-250 characters. Include Facebook/Twitter handles of involved schools/units/professors as appropriate.
A team led by @USCStemCell scientist Justin Ichida has identified 2 promising avenues for developing new treatments for diverse forms of ALS. Their findings are published in @CellStemCell and @CellCellPress. @KeckSchool_USC @NYSCF
Photo or Key Art Available *
Yes, I’m attaching it below.
Photo/Key Art Attachment #1
human_induced_motor_neurons_that_are_labeled_with_a_motor_neuron_marker_hb9_in_green_and_a_neuron_marker_tuj1_in_purple_courtesy_of_ichida_lab.tif
4.18 MB ? TIF
#1 Photo/Key Art Caption
Human induced motor neurons. Motor neurons are green, and neurons are purple.
#1 Photo/Key Art Credits
Courtesy of the Ichida Lab/USC Stem Cell

The post USC-led studies point the way to broadly effective treatments for ALS appeared first on USC News.

Fellowship funds medical student research program on skin of color

February 6, 2023

Patients of color face significant disparities across the health care system, and those inequities extend to dermatology. Delayed and incorrect diagnoses of skin conditions can lead to worse health outcomes–and even increase the risk of premature death–among people of color.

At the Keck School of Medicine of USC, the Skin of Color and Pigmentary Disorders Research Fellowship is part of a growing effort to reverse that trend. Each year, the fellowship program funds one medical student to study ethnic skin conditions and pigmentary disorders, learn about cultural competency, and engage in service learning. It is the only program of its kind in Southern California and one of just a few in the country.

“As my career has developed, I’ve seen an increased need for clinical and research programs related to skin of color, and I’m thrilled to be able to mentor students in this area,” said Nada Elbuluk, MD, associate professor of clinical dermatology at the Keck School of Medicine and founder and director of the fellowship.

The program is part of the larger USC Skin of Color Center and Pigmentary Disorders Program, also founded and directed by Elbuluk, which combines culturally sensitive dermatologic care with research on conditions that affect patients of color. The fellowship, launched in 2018, has received outside funding this year for the first time.

“We are honored and thankful for La Roche-Posay’s commitment to the work we are doing to improve dermatologic care for people of color and to improve health equity for all patients,” Elbuluk said.

This year’s fellow is Sarah Gonzalez, a medical student at Wayne State University in Detroit. She will work with Elbuluk to conduct research that may benefit patients around the world and contribute to service programs that support underserved and minority communities in the Los Angeles area.

“This is an opportunity of a lifetime. The research we are doing will hopefully bridge gaps of knowledge that will not only advance science but also decrease health disparities,” she said.

An understudied group

During the one-year fellowship, each medical student works closely with Elbuluk to conduct research on ethnic skin conditions and pigmentary disorders, an understudied branch of dermatology. They research conditions such as acne, alopecia and vitiligo, an autoimmune disorder that causes loss of skin pigmentation in patches.

Fellows also work alongside Elbuluk in the USC Skin of Color Center and Pigmentary Disorders Clinic, where they learn how to deliver culturally competent dermatologic care to patients of all skin types and backgrounds. The clinic provides specialized care for conditions that primarily affect people of color, such as keloids, an overgrowth of scar tissue. It also treats common skin conditions, including as acne, eczema and psoriasis, that may look different in patients of color due to the additional melanin in their skin.

In addition to the research and clinical training they receive, fellows participate in two community service initiatives: Dermmunity, which aims to increase education about skin health in underserved communities across Los Angeles, and DermRISES, which works to introduce underrepresented students to the sciences, medicine and dermatology.

Diversifying the workforce

Past fellows have authored numerous peer-reviewed publications related to skin of color, presented their findings at national scientific meetings and entered dermatology residency programs.

In addition to advancing research and clinical care for patients of color, the fellowship also plays a role in diversifying the physician workforce. In dermatology, only 3% of providers are Black and just 4% are Hispanic.

“Through this fellowship and mentoring these students, I also have the opportunity to help improve the pipeline of diverse applicants to the field of dermatology,” Elbuluk said.

To learn more about the Skin of Color and Pigmentary Disorders Research Fellowship, visit https://keck.usc.edu/dermatology/training-and-education/diversity-and-Inclusion/usc-skin-of-color-and-pigmentary-disorders-program.

The post Fellowship funds medical student research program on skin of color appeared first on USC News.

Study links adoption of electric vehicles with less air pollution, improved health

Electric vehicles are widely hailed as a key way to mitigate climate change through reduced emissions, but research on the dual benefits of reduced air pollution and improved health has been largely hypothetical.

A team of researchers from the Keck School of Medicine of USC have now begun to document the actual impact of electric vehicle adoption in the first study to use real-world data to link electric cars, air pollution and health. Leveraging publicly available datasets, the researchers analyzed a “natural experiment” occurring in California as residents in the state rapidly transitioned to electric cars, or light-duty zero emissions vehicles (ZEVs). The results were just published in the journal Science of the Total Environment.

The team compared data on total ZEV registration, air pollution levels and asthma-related emergency room visits across the state between 2013 to 2019. As ZEV adoption increased within a given zip code, local air pollution levels and emergency room visits dropped.

“When we think about the actions related to climate change, often it’s on a global level,” said Erika Garcia, PhD, MPH, an assistant professor of population and public health sciences at the Keck School of Medicine and the study’s lead author. “But the idea that changes being made at the local level can improve the health of your own community could be a powerful message to the public and to policy makers.”

The researchers also found that while total ZEVs increased over time, adoption was considerably slower in low-resource zip codes–what the researchers refer to as the “adoption gap.” That disparity points to an opportunity to restore environmental justice in communities that are disproportionately affected by pollution and related health problems.

“The impacts of climate change on health can be challenging to talk about because they can feel very scary,” said Sandrah Eckel, PhD, an associate professor of population and public health sciences at the Keck School of Medicine and the study’s senior author. “We’re excited about shifting the conversation towards climate change mitigation and adaptation, and these results suggest that transitioning to ZEVs is a key piece of that.”

Benefits for health and the climate

To study the effects of electric vehicle adoption, the research team analyzed and compared four different datasets. First, they obtained data on ZEVs (which includes battery electric, plug-in hybrid, and hydrogen fuel cell cars) from the California Department of Motor Vehicles and tabulated the total number registered in each zip code for every year between 2013 and 2019.

They also obtained data from U.S. Environmental Protection Agency air monitoring sites on levels of nitrogen dioxide (NO2), an air pollutant related to traffic, and zip code level asthma-related visits to the emergency room. Asthma is one of the health concerns long linked with air pollutants such as NO2, which can also cause and exacerbate other respiratory diseases, as well as problems with the heart, brain and other organ systems.

Finally, the researchers calculated the percentage of adults in each zip code who held bachelor’s degrees. Educational attainment levels are frequently used as an indicator of a neighborhood’s socioeconomic status.

At the zip code level, for every additional 20 ZEVs per 1,000 people, there was a 3.2% drop in the rate of asthma-related emergency visits and a small suggestive reduction in NO2 levels. On average across zip codes in the state, ZEVs increased from 1.4 to 14.6 per 1,000 people between 2013 and 2019. ZEV adoption was significantly lower in zip codes with lower levels of educational attainment. For example, a zip code with 17% of the population having a bachelor’s degree had, on average, an annual increase of 0.70 ZEVs per 1,000 people compared to an annual increase of 3.6 ZEVs per 1,000 people for a zip code with 47% of the population having a bachelor’s degree.

Past research has shown that underserved communities, such as lower-income neighborhoods, tend to face worse pollution and associated respiratory problems than more affluent areas. If ZEVs replace gas-powered cars in those neighborhoods, they could stand to benefit substantially.

“Should continuing research support our findings, we want to make sure that those communities that are overburdened with the traffic-related air pollution are truly benefiting from this climate mitigation effort,” Garcia said.

More to learn

While climate change is a massive health threat, mitigating it offers a massive public health opportunity, Eckel said. As one of the first studies to quantify the real-world environmental and health benefits of ZEVs, the research can help demonstrate the power of this mitigation measure, including possibly reduced health care utilization and expenditures.

The findings are promising, Garcia said, but many questions remain. Future studies should consider additional impacts of ZEVs, including emissions related to brake and tire wear, mining of materials for their manufacture, and disposal of old cars. The researchers also hope to study additional types of pollutants and other classes of vehicles, in addition to conducting a follow-up study of the effects of the ever-growing share of ZEVs in the state.

Moving forward, transitioning to ZEVs is just one part of the solution, Eckel said. Shifting to public transport and active transport, including walking and biking, are other key ways to boost environmental and public health.

 

About this study

In addition to Garcia and Eckel, the study’s other authors are Jill Johnston, Rob McConnell and Lawrence Palinkas from the Department of Population and Public Health Sciences, Keck School of Medicine of USC.

This work was supported by the University of Southern California Office of Research Strategic Directions for Research Award and the National Institute of Environmental Health Sciences [P30ES007048, P2CES033433].

Disclosure:

Erika Garcia reports stock in Tesla Inc., Rivian Automotive Inc., and Ford Motor Co., all outside the submitted work, a conflict of interest managed by the USC Health Science Campus Conflict of Interest Review Committee including independent review of data collection and analyses.

Sandrah Eckel reports having a spouse who works in emissions testing for a major automobile manufacturer, a conflict of interest managed by the USC Health Science Campus Conflict of Interest Review Committee including independent review of data collection and analyses

The post Study links adoption of electric vehicles with less air pollution, improved health appeared first on USC News.

New USC/Children’s Hospital Los Angeles lab to accelerate next-gen cell therapy

website *

New USC/CHLA cGMP Lab opens to accelerate next-generation cell therapy

Story Headline and Deck – USC News *
New USC/CHLA cGMP Lab opens to accelerate next-generation cell therapy

A new laboratory designed to advance early-stage research into lifesaving, commercially viable therapies was celebrated on the USC Health Sciences Campus Tuesday night.

Body Copy *
Housed at the USC Norris Comprehensive Cancer Center, the USC/CHLA cGMP Laboratory will manufacture cell and gene therapies under the Food and Drug Administration’s good manufacturing practice (cGMP) standards.

Therapies developed in the lab could one day be used to treat diseases such as arthritis, blindness and diabetes.

The 3,184-square-foot facility offers cleanrooms, laboratory space, cryostorage and state-of-the-art equipment for manufacturing and analytical testing. It was launched through a partnership between Children’s Hospital Los Angeles, Keck Medicine of USC and the Keck School of Medicine of USC.

The lab’s collaborative structure, broad expertise, specialized resources and regulatory knowledge will help accelerate big ideas and positive “disruption” to health care, said USC President Carol L. Folt, PhD.

“Effective partnerships can facilitate these breakthroughs while also supporting the steady, incremental and absolutely critical advancements” necessary to move an idea from lab to bedside, Folt said. “Billions of lives across the world could be changed by this work.”

Keck School of Medicine Dean Carolyn Meltzer, PhD, who began her position in March 2022, praised the countless hours teams spent bringing the idea to life.

“I came here because this institution really embodies interdisciplinary collaboration to solve the tough problems,” Meltzer said. “And this is a moment where we’re well positioned for disruptive growth and impact, which is really what’s most meaningful.”

The partnership demonstrates continued “representation of what world-class organizations can do working together,” said Paul Viviano, president and chief executive officer of CHLA, noting that his institution and USC have maintained an affiliation since 1932. “This magnificent center is a major step forward.”

The lab is part of a larger effort — the USC/CHLA Cell Therapy Program — to advance the science and translation of cell therapies at both institutions. (The program is tied to the USC+CHLA Alpha Clinic, which in November 2022 was awarded a five-year, $8 million grant from the California Institute for Regenerative Medicine.)

This effort marks continued momentum for expanding precision medicine. The cGMP lab’s multidisciplinary teams will work to further leverage the power of modified cells — as seen in CAR T-cell therapy, which reengineers patients’ immune cells to fight their own blood cancers — and apply them in new ways.

“The great thing about cell therapy is that patients are not passive receiving treatment; they are active participants,” said Mohamed Abou-el-Enein, MD, PhD, MSPH, executive director of the USC/CHLA Cell Therapy Program and director of the new cGMP lab.

The facility, he added, is “the missing puzzle piece that can enable us to bring homegrown discoveries to the clinic and to our patients.”

Abou-el-Enein expects the lab to serve 200 patients annually and partner with leading biotech companies. He also intends for it to help train a new generation of scientists and to prioritize pediatric and East Los Angeles patient populations.

Housing multiple parts of the development process under one roof offers a distinct advantage for researchers and patients, said Rod Hanners, chief executive officer of Keck Medicine.

“Cell-based therapies represent a quantum change in medical treatments,” Hanners said. “The establishment of the Translational Cell Therapy program between Keck Medicine of USC, Keck School of Medicine of USC and Children’s Hospital of Los Angeles, including the new cGMP facility, provides the collaboration, expertise and infrastructure to take new therapies and move them into clinical trials — all with the promise of curing diseases that affect our patient population.”

— Kevin Joy

The post New USC/Children’s Hospital Los Angeles lab to accelerate next-gen cell therapy appeared first on USC News.

Americans don’t know what’s a healthy blood pressure — and that’s a problem

8120 https://healthpolicy.usc.edu/article/false-confidence-in-blood-pressure-knowledge-undermines-intentions-to-seek-care/
Story Headline and Deck – USC News *
False Confidence in Blood Pressure Knowledge Undermines Intentions to Seek Care

Most Americans don’t know the meaning of 120/80 mm Hg, but think they do — and that’s a potential problem for their health.

Body Copy *
Nearly half of adults in the U.S. have high blood pressure (hypertension). In the long run, high blood pressure damages blood vessels, increases risk of heart failure, and leads to other poor health outcomes, especially in patients with additional conditions such as heart disease, kidney disease and diabetes. High blood pressure is more common as we get older, and a majority of people will develop blood pressure in their lifetime.

Yet, almost two-thirds of adults do not know the upper thresholds for normal or healthy blood pressure, according to a survey a new USC study published this week in the journal Medical Decision Making.

“High blood pressure usually has no symptoms,” said Wandi Bruine de Bruin , who co-directs the Behavioral Sciences program at the USC Schaeffer Center for Health Policy & Economics and is provost professor of public policy, psychology and behavioral sciences at the USC Price School of Public Policy. “So it is important to have your blood pressure tested, and to take action if it’s too high.”

While most survey participants did not correctly identify the threshold for healthy blood pressure, Bruine de Bruin and her team found that the majority were overly confident in their knowledge of blood pressure readings – and this false sense of confidence may be undermining their intentions to seek care for stage 1 hypertension.

What blood pressure numbers mean and when to seek care
Blood pressure is measured with two numbers. The top number, called systolic blood pressure, measures the pressure in our arteries when our hearts beat. The second number is called diastolic blood pressure and measures the pressure in our arteries when our hearts are resting between beats.

According to the American Heart Association, there are five blood pressure (BP) categories:

Table explaining blood pressure categories
The American Heart Association recommends that everyone with stage 1 hypertension talk to their doctor about making lifestyle changes, including eating a low-sodium diet, limiting alcohol use, being more physically active, maintaining a healthy weight, managing stress and quitting smoking. Medication is recommended for people with stage 2 hypertension and for some people with stage 1 hypertension, including those who also have heart disease, kidney disease or diabetes.

Confidence outpaces knowledge of what constitutes normal/healthy blood pressure
Bruine de Bruin and colleagues surveyed 6,592 U.S. adults, including 1,342 who had hypertension without comorbidities (heart disease, kidney disease, and diabetes) and 795 who had hypertension with comorbidities. They assessed whether survey participants could identify the threshold for normal/healthy blood pressure as well as their confidence in understanding blood pressure numbers.

Among the whole sample, 64% of participants expressed confidence in their understanding of blood pressure numbers but only 36% stated that 120/80 mm Hg was the upper threshold for normal/healthy blood pressure. When counting 120-130/80 mm Hg as correct, it was 39%.

Participants with high blood pressure without comorbidities were also more likely to be confident (78%) than knowledgeable (47%), when counting 120-130/80 mm Hg as correct. The same was true for participants who had high blood pressure with comorbidities who were slightly more confident (81%) but less knowledgeable (40%).

The researchers suggest that this false confidence may stem from repeated exposure to a topic. “We tend to feel more confident about topics that are more familiar. And blood pressure feels like a familiar topic because it gets measured at pretty much every healthcare visit,” says Bruine de Bruin. “But if these blood pressure measurements are not explained well or at all, we may develop false confidence. And that false confidence makes is feel that we know when to seek care, even when we don’t.”

Indeed, the researchers find that this false confidence in understanding blood pressure readings may undermine intentions to seek care. Survey participants who were confident were more likely to express intentions to act on stage 2 hypertension readings, but less likely to express intentions to act on stage 1 readings compared to those who were not confident.

“Identifying, treating, and controlling high blood pressure is a major clinical and public health challenge,” says coauthor Mark Huffman, professor of Medicine at Washington University in St. Louis. “We know that the earlier patients seek and receive treatment, the better and easier it is to control their blood pressure.”

Every doctor’s visit is an opportunity to talk about blood pressure
“Blood pressure is measured every time we go to the doctor as well as the dentist and other medical offices,” said Bruine de Bruin. “But knowledge about what these blood pressure numbers mean is not being transferred from the provider to the patient.”

It’s not clear why doctors skip opportunities to talk about managing high blood pressure. Possibly, doctors are desensitized to seeing stage 1 hypertension. High pressure is very common among adults across the U.S. Some people also have elevated blood pressure readings due to the stress or anxiety of being at a doctor’s office, which may lead doctors to take no action after seeing a high blood pressure reading.

But lowering blood pressure can help people stay healthy. In fact, a recent study showed that lowering systolic blood pressure by 5 mm Hg through medication reduces the risk of major cardiovascular events by 10%. Providing patients with information about blood pressure levels and behaviors and treatments they can do is an easy way to improve health, explained the researchers.

In addition to Bruine de Bruin and Huffman, Yasmina Okan (Pompeu Fabra University and Centre for Decision Research, Leeds University) and Tamara Krishnamurti (Center for Research on Health Care, University of Pittsburgh) coauthored the study. The survey was administered through the Understanding America Study at the USC Dornsife Center for Economic and Social Research.

The post Americans don’t know what’s a healthy blood pressure — and that’s a problem appeared first on USC News.

Social work researchers examine the health impacts of U.S. immigration policy

website *
https://dworakpeck.usc.edu/news/what-the-health-impact-on-deported-americans-returned-to-country-they-may-never-have-known
Story Headline and Deck – USC News *
Social work researchers examine the health impacts of U.S. immigration policy

Deporting immigrants to countries where they never lived is causing mental and physical health disparities for individuals and families.
Body Copy *
Immigration is one of the most controversial social and political issues in American life. Yet little attention is given to the aftermath of U.S. immigration policies or the immigrant Americans who are deported back to their country of origin. What is the resulting impact on mental and physical health disparities, both individually and at the societal level? This question is at the heart of groundbreaking research by scholars at the USC Suzanne Dworak-Peck School of Social Work.

Alice Cepeda, associate professor, and Avelardo Valdez, the Cleofas and Victor Ramirez Professor of Practice, Policy, Research and Advocacy for the Latino Population, have been studying disparities in health among deported Americans in Mexico City. They recently presented their important findings in a private audience with Ken Salazar, the United States Ambassador to Mexico, in hopes of expanding recognition for the impact current U.S. immigration policy is having on the lives of individuals and families.

“There are almost half a million deportees in Mexico City that are Americans,” Valdez said. “If you talk to these people, it’s like talking to any other U.S. citizen. Some of them have never even been to Mexico, have never even thought of going back, and suddenly find themselves in this strange country, separated and alienated from their families.”

Valdez and Cepeda have been working together to illuminate social and public health issues around Mexican American immigration and other factors for over 20 years. Their latest study funded by the National Institutes of Health – Disparities in Health among Floating Immigrant Populations – examines the health impacts of the U.S. immigration system. This study interviews recent immigrants in Los Angeles and deported Americans in Mexico City in order to identify mechanisms by which immigration processes expose individuals to distinct environments, increase susceptibility to risk behaviors and contribute to mental and physical health disparities, infectious diseases and alcohol/drug dependence. “Our goal with this research is to reframe immigration, not as a threat to public health, but instead recognizing immigrants’ special vulnerabilities from a human rights perspective,” Cepeda said. “The migration processes are something we really need to think about in terms of the health of these deported Americans, including mental health and substance use.”

Criminalizing the immigrant experience

When most people think of immigrants from Mexico to America they picture rural agricultural workers coming to work on farms in border states. However, many Mexican migrants to the United States today are from urban areas, and bound for major cities such as Los Angeles, Chicago or Atlanta to work in service sector jobs. Also in contrast to common wisdom, immigration from Mexico has actually decreased significantly in recent years, with 2 million fewer total unauthorized immigrants from Mexico living in the U.S. in 2017 than a decade earlier. This is attributable in part to a significant increase in deportations as a result of changes in immigration policy and the passage of laws specifically targeting immigrants. In 1996, the passage of the U.S. Illegal Reform and Immigrant Responsibility Act began the era of a deportation-carceral system that criminalizes immigrants, militarizes the border and removes long-term immigrants from the interior of the U.S. This law expanded the list of “deplorable” crimes that warranted deportation to include common misdemeanors such as identification or tax fraud, and making unauthorized re-entry into the U.S. a felony. In 2003, Immigration and Customs Enforcement (ICE) was created and expanded into the interior of the U.S., not just border areas, enlisting local law enforcement to apprehend unauthorized immigrants. Currently, immigration offenses are the most common federal crime, surpassing drug-related crime.

Many of these laws overwhelmingly target immigrants commonly known as “dreamers,” who came to the U.S. as children and might otherwise qualify for the Deferred Action for Childhood Arrivals (DACA) program to stay in the U.S. Because any criminal history, even misdemeanors, violates the DACA morality clause, these laws have the net effect of criminalizing immigration. For this reason, Cepeda and Valdez often refer to the deported Americans in Mexico City as the “other dreamers.” These deportees also create a new form of family separation. Among the deported Americans Cepeda and Valdez have surveyed in their study,45% report they left behind one or more children in the U.S., many of them U.S. citizens, disrupting the family’s primary financial support and creating tremendous anxiety and stress across the family.

One of the men Cepeda and Valdez interviewed personifies this dynamic. A 36-year-old married man with several children, residing in Dallas and earning a living as a contractor with six employees, was pulled over for a minor traffic infraction. Due to this immigration status, he was deported to Mexico, a place he had not been for over twenty years. His wife and children were suddenly left with no financial support and his employees without jobs. In an effort to keep his family together, he tried moving his wife and children to Mexico, but they were unable to acclimate to the social systems and language, eventually returning to the U.S. Now, his wife visits him occasionally in Mexico, but the children, who feel uncomfortable in Mexico, only communicate with their father by phone.

“Like they deported us to a war zone”

Many of these deported Americans do not remember Mexico or even speak Spanish. Suddenly they find themselves in a country with an unfamiliar system, struggling to survive, and the physical and emotional stresses of this journey taking a significant toll.

“This is a population that is dealing with very high, severe mental health issues and anxiety, distress, ecological distress,” Cepeda said. “We really wanted to look at how these distinct immigration experiences contribute to these outcomes. It’s not just the immigration itself, it’s the transit to the destination, the interception, and then now coming back.”

Valdez says that most of the people who are deported to Mexico City have no family ties at all in the area. They are just thrown into the city and then have to find a place to live and a job, with almost no support from the U.S. or Mexico.

“It’s like they deported us to a war zone, one we don’t know anything about,” said one 25-year-old deported American interviewed for the study who came to the U.S. at three years old and lived in Indiana until being returned to Mexico in 2018. “I grew up in the States all my life and they deport me when I’m an adult to someplace where I don’t know how to file my taxes, get a job or get my ID. The only option you’re giving us is to commit more crimes, because we don’t know what to do.”

Valdez and Cepeda anticipate their study will stimulate discussion and lead to the implementation of policies and programs by both the U.S. and Mexico governments that address these inequities in mental and health conditions for this population.

The post Social work researchers examine the health impacts of U.S. immigration policy appeared first on USC News.